Physician profile
Gregory Mathews
NPI 1265529374
$30,235.24
in general payments reported to CMS, 2019-2025
48 companies · $2,131 in 2025
The $2,131 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,027 · 2020: $3,853 · 2021: $4,127 · 2022: $5,156 · 2023: $5,991 · 2024: $7,951 · 2025: $2,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $3,911 · Travel and Lodging: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,028.00 |
| Food and Beverage | $3,910.78 |
| Travel and Lodging | $133.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $20,217.03 | 2020-2025 | Valtoco |
| Supernus Pharmaceuticals, INC. | $1,630.82 | 2019-2023 | Oxtellar Xr |
| Lilly USA, LLC | $1,333.09 | 2019-2024 | Mounjaro, Emgality, Reyvow |
| Sunovion Pharmaceuticals INC. | $968.19 | 2019-2022 | |
| Ucb, INC. | $745.99 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Novo Nordisk INC | $445.56 | 2019-2024 | Ozempic, Rybelsus |
| Sumitomo Pharma America, INC. | $406.66 | 2023-2024 | Aptiom |
| Corcept Therapeutics | $357.73 | 2019-2024 | Korlym |
| Abbvie INC. | $346.12 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $341.66 | 2020-2024 | Austedo Xr, Ajovy, Austedo |
| Amgen INC. | $312.27 | 2020-2024 | Evenity, Prolia |
| Livanova USA, INC. | $302.48 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Sk Life Science, INC. | $259.49 | 2021-2025 | |
| Eisai INC. | $212.74 | 2019-2023 | |
| Pfizer INC. | $212.46 | 2021-2025 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Mathews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.